Based on the in vitro and ex vivo data, we hypothesized that the combinations of a type II JAK2 inhibitor and an mTOR inhibitor would achieve better anti-leukemia control in the in vivo Ph-like B-ALL PDX models. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.